Actively Recruiting

Phase 2
Age: 21Years +
FEMALE
NCT06477406

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

Led by Mclean Hospital · Updated on 2026-03-30

30

Participants Needed

1

Research Sites

117 weeks

Total Duration

On this page

Sponsors

M

Mclean Hospital

Lead Sponsor

M

Massachusetts Life Sciences Center

Collaborating Sponsor

AI-Summary

What this Trial Is About

Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. This project will provide information that does not currently exist on the potential efficacy of a cannabinoid-based sublingual product for endometriosis.

CONDITIONS

Official Title

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

Who Can Participate

Age: 21Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Subject has provided informed consent
  • Sex assigned female at birth
  • Subject is 21 or older
  • Subject is fluent in English
  • Subject endorses at least moderate levels of pain at the baseline visit
  • Subject endorses having endometriosis
Not Eligible

You will not qualify if you...

  • Non-fluent English speakers
  • Endorsement of current substance use disorder, psychotic disorder, or an eating disorder
  • Currently uses cannabis or cannabinoid products regularly
  • Patients will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding
  • Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper/hypotension, cardiac disorders), or neurological disorder (including seizure disorder)
  • Neuropathic pain or cancer-related pain
  • Disclosure of a genetic polymorphism affecting CYP2C9 function

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

McLean Hospital

Belmont, Massachusetts, United States, 02478

Actively Recruiting

Loading map...

Research Team

S

Staci Gruber, PhD

CONTACT

R

Rosie Smith, M.S.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

NON_RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here